NICE recommendations for ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has recommended Remicade (infliximab; Merck Sharp & Dohme), Humira (adalimumab; Abbvie) and Simponi (golimumab; Merck Sharp & Dohme), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. Simponi is recommended only if Merck Sharp & Dohme provides the 100mg dose at the same cost as the 50mg dose, as agreed in the patient access scheme.
Additionally, NICE recommends Remicade as an option for treating severely active ulcerative colitis in children and young people aged 6–17 years with the same conditions as above.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067435